查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715656

GLP-1 受体促效剂市场（按药物类别、药物类型、给药途径、应用和分销管道划分）—2025 年至 2030 年全球预测

GLP-1 Receptor Agonist Market by Drug Class, Drug Type, Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

GLP-1受体促效剂市场预计到2024年将达到403.1亿美元，到2025年将达到455.9亿美元，到2030年将达到855.5亿美元，复合年增长率为13.36%。

主要市场统计数据
基准年2024年 403.1亿美元
预计2025年 455.9亿美元
预测年份 2030 855.5亿美元
复合年增长率（%） 13.36%

GLP-1 受体促效剂市场已成为科学创新与快速发展的医疗保健相结合的充满活力的领域。近年来，随着胜肽类治疗药物的进步，GLP-1受体促效剂因对第二型糖尿病、肥胖症等疾病有明显疗效而备受关注。 GLP-1 受体促效剂市场结合了严谨的研究和可靠的临床结果，其特点是技术创新、策略合作和更注重以患者为中心的护理。

慢性代谢疾病的出现推动了对不仅能控制血糖值，还能提供减肥和心血管支持等其他益处的治疗的需求。因此，製药相关人员正在增加对该领域的投资，并突破传统治疗模式的界限。

此外，监管变化和不断发展的报销框架的作用也不容小觑，因为这些因素正在不断重塑市场进入和竞争动态。这些因素的相互作用表明，未来的治疗策略将以更个人化、更有效、更容易获得的 GLP-1 受体促效剂为主。在这种不断变化的情况下，对于那些希望驾驭和影响这个高风险市场的人来说，了解基本趋势、细分、区域需求和关键行业参与者至关重要。

改变 GLP-1 受体促效剂市场

由于各种科学、临床和市场因素，GLP-1受体促效剂周围的环境正在发生重大变化。近年来，在先进配方技术和对细胞层面上药物交互作用的更深入了解的推动下，开创性的研究正在重新定义治疗标准。新的临床试验模式不仅改善了患者的治疗效果，还扩大了现有治疗方法的适应症并将其整合到更广泛的疾病管理方案中。

这项变化背后的关键力量是药品和数位健康解决方案的整合。增强的病患监测、数据分析和即时回馈机制有助于实现更全面的治疗方法。这些技术进步不仅提高了功效；他们还正在改变治疗依从性和病人参与的管理方式。

同时，各地区监管机构正在简化核准流程，以加快新型 GLP-1 疗法的市场准入，同时确保安全性。研究机构、生技公司和大型製药公司之间的策略联盟也正在创造一个跨学科知识推动治疗创新的环境。因此，对患者友善且经济可行的治疗方法正在迅速发展。

随着产业竞争日益激烈，各公司正在完善研发策略、重新调整临床试验设计并进行有针对性的行销宣传活动。将真实证据和高级分析纳入决策流程现在至关重要。这种转变不仅为下一代治疗解决方案铺平了道路，也为更能适应患者照护和成本效益的细微差别的市场环境铺平了道路。

GLP-1受体促效剂市场的关键细分洞察

GLP-1 受体促效剂市场在多个维度上错综复杂地细分，为市场趋势和机会提供了关键见解。按药物类别进行更深入的分析显示，市场对Dulaglutide、Liraglutide和Semaglutide等关键成分进行了探索，每种成分都表现出独特的临床和药理特性，推动了不同患者群体的采用。此外，从药物类型中获得的见解表明，长效和短效激动剂在满足特定患者需求方面都发挥着重要作用，长效促效剂提供持续的治疗效果，短效促效剂在急性期提供快速作用。

给药途径进一步说明了市场的多样性，分析重点是口服和非注射製剂。这项双模式研究将有助于了解患者偏好以及与不同给药方法相关的物流细微差别。此外，按应用细分突出了 GLP-1 受体促效剂在心血管疾病、糖尿病管理和体重管理中作为综合治疗通讯协定的关键驱动因素的作用。这些应用对于控制併发症和改善患者的整体健康至关重要。

此外，分销通路分析强调了针对市场客製化方法的重要性，并从医院药局、网路药局和零售药局等管道获得了见解。这种细分有助于相关人员了解患者取得药物的不同途径，从而製定有针对性的策略来优化市场渗透率。从治疗层级到分销管道，每个细分参数都提供了对 GLP-1 受体促效剂市场固有的机会和挑战的详细了解，指南策略决策和资源分配。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球糖尿病和肥胖症盛行率上升
      • 世界人口老化以及人们对文明病的认识不断提高
      • 政府措施和不断上涨的医疗成本
    • 限制因素
      • 医疗费用上涨和副作用
    • 机会
      • 药物输送系统的进步提高了病患的依从性和便利性
      • 策略合作与伙伴关係加速研发
    • 任务
      • 策略合作与伙伴关係加速研发
  • 市场区隔分析
    • 药物类型：由于患者的依从性因素及其适合更广泛的慢性病治疗模式，长效促效剂的采用正在增加。
    • 应用：扩大GLP-1受体促效剂作为抗糖尿病药物的偏好，以改善血糖控制
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. GLP-1受体促效剂市场（依药物类别）

  • Dulaglutide
  • Liraglutide
  • Semaglutide

7. GLP-1受体促效剂市场（依药物类型）

  • 长效促效剂
  • 短效促效剂

8. GLP-1受体促效剂市场（依给药途径）

  • 口服
  • 肠外

9. GLP-1受体促效剂市场（依应用）

  • 心血管健康
  • 糖尿病管理
  • 体重管理

第 10 章 GLP-1 受体促效剂市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

11. 美洲 GLP-1 受体促效剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区 GLP-1 受体促效剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲 GLP-1 受体促效剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Amgen Inc.
  • AstraZeneca Inc.
  • Bachem Group
  • Biopharma PEG
  • Boehringer Ingelheim International GmbH
  • Calibrate Health, Inc.
  • Cleveland Clinic
  • Daiichi Sankyo Company, Limited
  • Diabetes UK
  • Eli Lilly and Company
  • GenScript
  • GlaxoSmithKline plc
  • GoodRx, Inc.
  • Hanmi Pharm.Co.,Ltd.
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Patsnap（UK）Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Twist Bioscience Corporation
  • WebMD LLC.
Product Code: MRR-B9334AD6C5EF

The GLP-1 Receptor Agonist Market was valued at USD 40.31 billion in 2024 and is projected to grow to USD 45.59 billion in 2025, with a CAGR of 13.36%, reaching USD 85.55 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 40.31 billion
Estimated Year [2025] USD 45.59 billion
Forecast Year [2030] USD 85.55 billion
CAGR (%) 13.36%

The GLP-1 receptor agonist market has emerged as a dynamic field where scientific innovation meets a rapidly evolving healthcare landscape. In recent years, advancements in peptide-based therapies have propelled GLP-1 receptor agonists into the spotlight due to their proven efficacy in managing conditions such as type 2 diabetes and obesity. This market represents a convergence of rigorous research and robust clinical outcomes, and it is characterized by a blend of technological innovation, strategic collaborations, and an increasing focus on patient-centric treatments.

The onset of chronic metabolic diseases has catalyzed the demand for treatments that not only manage blood glucose levels but also offer additional benefits such as weight reduction and cardiovascular support. As a result, stakeholders across the pharmaceutical industry have escalated their investments in this sector, pushing the boundaries of traditional treatment paradigms.

Moreover, the role of regulatory shifts and evolving reimbursement frameworks cannot be understated, as these factors continuously reshape market access and competitive dynamics. The interplay of these dimensions suggests a future where more personalized, effective, and accessible collections of GLP-1 receptor agonists dominate therapeutic strategies. In this evolving scenario, understanding the underlying trends, segmentation, regional demands, and key industry players is essential for anyone seeking to navigate or influence this high-stakes market.

Transformative Shifts in the GLP-1 Receptor Agonist Landscape

The landscape of GLP-1 receptor agonists is witnessing profound transformations owing to a range of scientific, clinical, and market-driven forces. Recent years have seen innovative research redefining therapy standards, driven by advanced formulation techniques and a deeper understanding of drug interactions at the cellular level. New clinical trial paradigms have not only improved patient outcomes but have also expanded the indications for existing therapies, integrating them into broader disease management protocols.

A critical force behind these changes is the integration of digital health solutions alongside pharmaceuticals. Enhanced patient monitoring, data analytics, and real-time feedback mechanisms have facilitated a more holistic approach to therapy. These technical advancements are not just limited to improving efficacy but are also transforming how treatment adherence and patient engagement are managed.

Simultaneously, regulatory bodies across various geographies have streamlined approval processes without compromising on safety, thereby accelerating market entry for new GLP-1 therapies. Strategic alliances between research institutions, biotechnology firms, and pharmaceutical giants are also fostering an environment where cross-disciplinary knowledge propels therapeutic innovation. This has resulted in the rapid evolution of treatment modalities that are both patient-friendly and economically viable.

As the industry becomes increasingly competitive, companies are refining their research and development strategies, recalibrating clinical trial designs, and deploying targeted marketing campaigns. The incorporation of real-world evidence and advanced analytics in decision-making processes is now fundamental. These transformative shifts are setting the stage not only for next-generation therapeutic solutions but also for a market landscape that is more responsive to the nuances of patient care and cost efficiency.

Key Segmentation Insights in the GLP-1 Receptor Agonist Market

The GLP-1 receptor agonist market is intricately segmented along multiple dimensions that provide vital insight into market behavior and opportunities. A deep analysis based on drug class reveals that the market is studied across critical components such as Dulaglutide, Liraglutide, and Semaglutide, each exhibiting unique clinical and pharmacological profiles that drive their adoption in diverse patient populations. Furthermore, insights derived from studying drug type indicate that both Long-Acting Agonists and Short-Acting Agonists play a significant role in addressing specific patient needs, where long-acting formulations offer sustained therapeutic benefits and short-acting ones provide rapid action during acute phases.

The route of administration further illustrates the market's versatility with analytical focus on both Oral and Parenteral forms. This dual-mode study supports an understanding of patient preferences and the logistical nuances associated with different delivery methods. In addition, the application-based segmentation underscores the importance of GLP-1 receptor agonists, with their roles in Cardiovascular Health, Diabetes Management, and Weight Management driving comprehensive treatment protocols. These applications are critical in managing comorbidities and enhancing overall patient health outcomes.

Moreover, the distribution channel analysis highlights the importance of tailored market approaches, as insights are drawn from channels including Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. This segmentation allows stakeholders to understand the varied paths through which patients access medications and enables targeted strategies to optimize market penetration. Each segmentation parameter, from therapeutic class to distribution channel, offers a granular understanding of the opportunities and challenges inherent in the GLP-1 receptor agonist market, thereby guiding strategic decision-making and resource allocation.

Based on Drug Class, market is studied across Dulaglutide, Liraglutide, and Semaglutide.

Based on Drug Type, market is studied across Long-Acting Agonists and Short-Acting Agonists.

Based on Route of Administration, market is studied across Oral and Parenteral.

Based on Application, market is studied across Cardiovascular Health, Diabetes Management, and Weight Management.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Dynamics Shaping the Market

Regional dynamics play an instrumental role in shaping market outcomes for GLP-1 receptor agonists. In the Americas, strong healthcare infrastructure combined with high rates of metabolic disorders has led to significant investments in treatment advancements and patient education programs. The regulatory environment in this region supports accelerated drug approvals, fostering a competitive yet nurturing ecosystem for innovator and biosimilar approaches alike.

In Europe, the Middle East, and Africa, a unique mix of established and emerging healthcare markets is evident. These regions benefit from robust research frameworks, strong governmental support for innovative healthcare solutions, and rising awareness regarding chronic disease management. Strategic collaborations and public-private partnerships have spurred local innovations and facilitated improved accessibility to advanced GLP-1 therapies.

Across the Asia-Pacific, rapid urbanization, increasing healthcare demands, and evolving lifestyle trends have spurred a burgeoning market for GLP-1 receptor agonists. Emerging economies in this region are increasingly prioritizing healthcare reforms and investing in infrastructure that allows for advanced diagnostic and therapeutic interventions. The diverse regional market dynamics not only reflect varied healthcare ecosystems but also highlight the multifaceted challenges and opportunities that companies must navigate to achieve sustainable growth across different geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights into Key Industry Players

The competitive landscape of the GLP-1 receptor agonist market is enriched by the active participation of multiple high-caliber companies, each contributing unique strengths to overall market innovation and patient care. Leading organizations such as Amgen Inc. and AstraZeneca Inc. have demonstrated unwavering commitment to research excellence and robust clinical applications. Their substantial investments in R&D have paved the way for significant leaps in the formulation and delivery of GLP-1 receptor agonists.

Notably, organizations like Bachem Group and Biopharma PEG have carved niches in manufacturing and bioconjugation technologies, supporting the complex production requirements intrinsic to peptide-based therapies. Esteemed institutions including Boehringer Ingelheim International GmbH, Calibrate Health, Inc., and the Cleveland Clinic have fostered multidisciplinary collaborations that reinforce the clinical credibility of therapeutic applications.

The presence of companies such as Daiichi Sankyo Company, Limited and Diabetes UK further underscores the market's commitment to patient-centric innovations, while Eli Lilly and Company and GenScript continue to lead in biotherapeutic advances. Well-established players like GlaxoSmithKline plc and GoodRx, Inc. ensure wide market reach and robust supply chain strategies, complementing the innovative strides made by Hanmi Pharm.Co.,Ltd. and Innovent Biologics, Inc.

The pharmaceutical landscape is further diversified by regional and global influencers including Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., and Novo Nordisk A/S, who bring extensive clinical expertise to the table. Oramed Pharmaceuticals Inc. and Patsnap (UK) Ltd. add valuable perspectives by pioneering novel delivery systems and market intelligence analytics. The contributions of Pfizer Inc., Sanofi SA, and Sun Pharmaceutical Industries Ltd. are instrumental in sustaining competitive dynamics, while Twist Bioscience Corporation and WebMD LLC offer technological insights that assist in bridging clinical practice with patient engagement. Collectively, these companies embellish the market with a rich tapestry of research, innovation, and strategic vision, fostering an environment where groundbreaking therapies can thrive.

The report delves into recent significant developments in the GLP-1 Receptor Agonist Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca Inc., Bachem Group, Biopharma PEG, Boehringer Ingelheim International GmbH, Calibrate Health, Inc., Cleveland Clinic, Daiichi Sankyo Company, Limited, Diabetes UK, Eli Lilly and Company, GenScript, GlaxoSmithKline plc, GoodRx, Inc., Hanmi Pharm.Co.,Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Patsnap (UK) Ltd., Pfizer Inc, Sanofi SA, Sun Pharmaceutical Industries Ltd., Twist Bioscience Corporation, and WebMD LLC.. Actionable Recommendations for Industry Leaders

To capitalize on the multifaceted opportunities within the GLP-1 receptor agonist market, industry leaders must activate an agile, data-driven strategy that encompasses both innovation and market expansion. First, prioritizing substantial investments in research and development is critical. Leaders should channel resources into enhancing clinical trial designs and engaging in cross-functional collaborations that bridge the gap between laboratory breakthroughs and real-world patient outcomes.

In addition, it is advisable for companies to conduct deep-dive analyses into market segmentation to identify under-served patient cohorts and emerging therapeutic niches. Leveraging insights from the diverse segmentation like drug classes, drug types, and routes of administration can reveal hidden efficiencies and patient adherence trends that ultimately drive commercial success. Furthermore, expanding distribution strategies by integrating digital channels with traditional supply networks will enable broader and more efficient market penetration.

Industry stakeholders should also take an active role in influencing policy reforms and regulatory frameworks. Engaging with regional regulators and participating in public-private partnerships can lead to more favorable market conditions and smoother pathways for product introductions. Moreover, adopting personalized marketing strategies that address the varied cultural and economic backgrounds of patient populations can elevate brand trust and loyalty.

Finally, building a robust ecosystem that synergizes innovation, patient support, and strategic alliances will be pivotal. Companies should invest in comprehensive market intelligence platforms that provide real-time data and predictive analytics, ensuring that every strategic decision is backed by actionable insights. This multi-pronged approach will not only ensure sustained market leadership but also empower companies to navigate the complex interplay of science, technology, and patient care with confidence.

Conclusion and Market Outlook

The GLP-1 receptor agonist market stands at a transformative juncture where impressive scientific advancements and dynamic market forces converge to redefine patient treatment paradigms. A critical review of market trends reveals that significant opportunities lie in the sectors of personalized medicine, innovative drug delivery systems, and enhanced patient care protocols. The integration of advanced technological solutions with traditional pharmaceutical research has set the stage for sustained growth, driven by dynamic clinical research and robust regulatory support.

As the market continues to evolve, the dual emphasis on improving efficacy and addressing real-world therapeutic challenges will serve as the bedrock for competitive differentiation. The interplay between demand-side pressures from chronic disease prevalence and supply-side innovations creates an environment where agility, collaboration, and a relentless focus on patient outcomes are indispensable. The comprehensive segmentation and regional analyses provide a framework that not only highlights existing market strengths but also underscores areas of untapped potential.

In summary, the future trajectory of the GLP-1 receptor agonist landscape is promising, with key players and strategic initiatives collaborating to overcome challenges and expand reach. By leveraging a nuanced understanding of market segmentation, regional variances, and competitive dynamics, stakeholders are well-positioned to harness new growth avenues and set a benchmark in therapeutic excellence. The commitment to continuous innovation and strategic partnerships will undeniably shape the future of metabolic disease management and related therapeutic disciplines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Global rise in the prevalence of diabetes and obesity
      • 5.1.1.2. Aging global population and growing awareness about lifestyle diseases
      • 5.1.1.3. Increasing government initiatives and healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and adverse side effects
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug delivery systems to improve patient adherence and convenience
      • 5.1.3.2. Strategic collaborations and alliances to accelerate the research and development
    • 5.1.4. Challenges
      • 5.1.4.1. Strategic collaborations and alliances to accelerate the research and development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing adoption of long-acting agonists due to patient compliance factors and their fitting into a broader chronic care model
    • 5.2.2. Application: Expanding preferences of GLP-1 receptor agonists as anti-diabetic medications improving glycemic control
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. GLP-1 Receptor Agonist Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Dulaglutide
  • 6.3. Liraglutide
  • 6.4. Semaglutide

7. GLP-1 Receptor Agonist Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Long-Acting Agonists
  • 7.3. Short-Acting Agonists

8. GLP-1 Receptor Agonist Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. GLP-1 Receptor Agonist Market, by Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Health
  • 9.3. Diabetes Management
  • 9.4. Weight Management

10. GLP-1 Receptor Agonist Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas GLP-1 Receptor Agonist Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific GLP-1 Receptor Agonist Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa GLP-1 Receptor Agonist Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Novo Nordisk collaborate with Ascendis for innovation in monthly GLP-1 receptor agonists
    • 14.3.2. Pfizer advances the development of oral GLP-1 receptor agonist for Type 2 diabetes
    • 14.3.3. Teva Pharmaceuticals improves diabetes care by launching the first generic GLP-1 receptor agonist in the U.S.
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca Inc.
  • 3. Bachem Group
  • 4. Biopharma PEG
  • 5. Boehringer Ingelheim International GmbH
  • 6. Calibrate Health, Inc.
  • 7. Cleveland Clinic
  • 8. Daiichi Sankyo Company, Limited
  • 9. Diabetes UK
  • 10. Eli Lilly and Company
  • 11. GenScript
  • 12. GlaxoSmithKline plc
  • 13. GoodRx, Inc.
  • 14. Hanmi Pharm.Co.,Ltd.
  • 15. Innovent Biologics, Inc.
  • 16. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 17. Merck & Co., Inc.
  • 18. Novo Nordisk A/S
  • 19. Oramed Pharmaceuticals Inc.
  • 20. Patsnap (UK) Ltd.
  • 21. Pfizer Inc
  • 22. Sanofi SA
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Twist Bioscience Corporation
  • 25. WebMD LLC.

LIST OF FIGURES

  • FIGURE 1. GLP-1 RECEPTOR AGONIST MARKET MULTI-CURRENCY
  • FIGURE 2. GLP-1 RECEPTOR AGONIST MARKET MULTI-LANGUAGE
  • FIGURE 3. GLP-1 RECEPTOR AGONIST MARKET RESEARCH PROCESS
  • FIGURE 4. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLP-1 RECEPTOR AGONIST MARKET DYNAMICS
  • TABLE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 235. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2024